CBD-Rich Cannabis Strains Available in the UK: What Patients Should Know

For patients navigating medical cannabis treatment in the United Kingdom, understanding the differences between high-CBD strains, their classification as indica, sativa, or hybrid, and how they interact with the body is essential. This guide, prepared with input from the Cannamedical Britannia clinical team, covers everything you need to know before speaking with your prescribing clinician.

What Are High-CBD Medical Cannabis Strains?

Cannabidiol (CBD) is one of over 100 cannabinoids found in the Cannabis sativa plant. Unlike tetrahydrocannabinol (THC), CBD does not produce psychoactive effects but interacts with the body’s endocannabinoid system (ECS) to modulate pain, inflammation, anxiety, and sleep. High-CBD strains are defined as those containing a CBD:THC ratio of 2:1 or greater, though many medicinal varieties carry ratios as high as 20:1 or even isolate pure CBD.

In the UK, medical cannabis was legalised for prescription in November 2018 under Schedule 2 of the Misuse of Drugs Regulations. Patients cannot purchase cannabis-based medicinal products (CBMPs) over the counter; they must be prescribed by a specialist clinician on the General Medical Council register. All products dispensed through licensed UK pharmacies must meet strict pharmaceutical standards, including EU-GMP certification — the same quality framework applied to conventional medicines.

Cannamedical Britannia sources its portfolio exclusively from EU-GMP certified cultivators across more than 30 partner facilities, ensuring consistent cannabinoid profiles, terpene content, and microbiological safety for every batch dispensed to UK patients.

Indica vs Sativa vs Hybrid: Does It Matter for Medical Patients?

The traditional botanical classification of cannabis into indica and sativa subspecies originated in 18th-century taxonomy and described plant morphology — not pharmacological effect. Contemporary cannabis science has moved significantly beyond this framework, and the British Journal of Pharmacology has published extensively on how terpene profiles and cannabinoid ratios are far more predictive of patient response than botanical classification.

That said, the indica/sativa/hybrid terminology persists in clinical formularies and patient communications because it provides a useful shorthand, provided patients understand its limitations:

• Indica-dominant strains are commonly associated with sedating, body-focused effects, often attributed to higher myrcene content. Frequently prescribed for pain management, muscle spasm, and sleep disorders.
• Sativa-dominant strains tend toward more energising, cerebral effects, often linked to limonene and pinene terpenes. May be better suited to daytime use and conditions such as fatigue associated with chronic illness.
• Hybrid strains combine characteristics of both, offering clinicians more nuanced tools for tailoring treatment. The majority of EU-GMP certified products in UK formularies are hybrid varieties.

Your prescribing specialist will not simply ask “indica or sativa?” — they will review your condition, prior treatments, tolerance, and lifestyle before recommending a specific product with defined CBD and THC percentages. Visit our UK patient guide for a broader introduction to the prescription process.

The Entourage Effect: Why CBD and THC Work Together

One of the most clinically relevant concepts in medical cannabis pharmacology is the entourage effect — the theory, supported by a growing body of peer-reviewed evidence, that cannabinoids, terpenes, and flavonoids in the whole cannabis plant work synergistically to produce effects greater than isolated compounds alone.

Seminal work published in the British Journal of Pharmacology by Russo (2011) proposed that CBD modulates the psychoactive properties of THC, reducing anxiety and cognitive impairment while potentially enhancing analgesic efficacy. This is why many UK clinicians now prescribe balanced CBD:THC products rather than CBD isolate alone, particularly for conditions such as neuropathic pain, spasticity in multiple sclerosis, and treatment-resistant epilepsy.

Key terpenes that contribute to the entourage effect include:

• Myrcene — the most abundant terpene in most cannabis varieties. Produces earthy, musky aromas. Associated with sedating, analgesic properties and enhanced mucosal absorption of cannabinoids. Commonly found in indica-dominant medical strains such as Bediol.
• Limonene — citrus-scented terpene with anxiolytic and antidepressant properties according to preclinical research. Often found in sativa-leaning varieties and may support patients managing anxiety alongside chronic conditions.
• Caryophyllene — unique among terpenes in that it directly binds to CB2 receptors in the endocannabinoid system. Associated with anti-inflammatory effects and may be particularly beneficial for patients with inflammatory conditions such as arthritis or Crohn’s disease.
• Linalool — floral, lavender-adjacent terpene associated with calming, anxiolytic effects. Often present in indica-dominant strains prescribed for anxiety and sleep disorders.
• Pinene — found in alpha and beta forms. Associated with bronchodilation and potential counter-effects on THC-induced short-term memory impairment. More prevalent in sativa-dominant varieties.

Understanding terpene profiles is increasingly central to personalised cannabis medicine. Cannamedical Britannia provides full certificate of analysis (CoA) data for all products, including terpene content, to support shared clinical decision-making. Learn more about our clinical resources for prescribers.

Popular High-CBD Cannabis Strains Available in UK Clinics

The following strains are among those most frequently discussed in UK clinical settings. Availability varies by clinic formulary and dispensing pharmacy. All products prescribed in the UK must be licensed CBMPs or unlicensed specials meeting MHRA standards.

Strain	Type	CBD%	THC%	Key Terpenes	Best For
Bediol	Hybrid	9%	6%	Myrcene, Caryophyllene	Pain, Muscle Spasm, Sleep
Bedrobinol	Hybrid	1%	13.5%	Myrcene, Limonene	Severe Pain, Spasticity (MS)
Harlequin	Sativa-dominant	10-15%	4-7%	Myrcene, Caryophyllene, Pinene	Chronic Pain, Anxiety, Daytime Use
Charlotte’s Web	Hybrid	17-20%	<0.3%	Myrcene, Caryophyllene, Linalool	Epilepsy, Anxiety, Inflammation
ACDC	Hybrid	14-20%	1-6%	Myrcene, Pinene, Caryophyllene	Anxiety, Pain, Neurodegenerative Conditions
Cannatonic	Hybrid	6-17%	6%	Myrcene, Limonene	Muscle Spasm, Anxiety, Migraines
Ringo’s Gift	Hybrid	15-24%	<1%	Caryophyllene, Myrcene	High-CBD Protocol, Pain Management

CBD and THC percentages represent typical batch ranges from EU-GMP certified sources. Actual product specifications will be confirmed by your dispensing pharmacist via certificate of analysis.

Cannamedical Britannia’s portfolio, drawn from 30+ EU-GMP certified cultivators and encompassing 100+ products, includes both whole flower and extract-based formats. The breadth of available cultivars allows prescribing clinicians to match specific cannabinoid and terpene profiles to individual patient needs rather than relying on generic formulations. Explore the full strain library for detailed product information.

Which Strain Type Is Best for Your Condition?

There is no universally “best” strain for any given condition — prescribing decisions are based on the totality of a patient’s clinical picture. However, clinical experience and emerging evidence suggest the following general patterns:

Chronic Pain and Neuropathic Pain

Balanced CBD:THC products (ratios between 1:1 and 2:1) are most commonly prescribed for neuropathic and chronic pain conditions. Indica-dominant or hybrid varieties with high myrcene content are frequently preferred for evening and night-time dosing due to their sedating properties. Harlequin and Bediol are among the most-studied options in this category.

Anxiety and PTSD

High-CBD, low-THC strains are generally preferred. THC at higher concentrations can exacerbate anxiety in some patients; CBD has demonstrated anxiolytic properties in several clinical trials. Sativa-dominant, limonene-rich varieties may be suitable for daytime management of anxiety, whilst indica-leaning, linalool-rich strains may support sleep and night-time symptom control in PTSD.

Multiple Sclerosis and Spasticity

Bedrobinol and similar THC-dominant products with moderate CBD content are frequently included in MS treatment protocols. The NICE Technology Appraisal for nabiximols (Sativex) — a 1:1 CBD:THC oromucosal spray — confirmed efficacy for spasticity in MS, providing a clinical framework for whole-plant prescribing in this indication.

Epilepsy

Charlotte’s Web and other very high-CBD, near-zero-THC strains have the strongest evidence base for epilepsy, particularly treatment-resistant childhood epilepsy syndromes. Epidiolex (pharmaceutical-grade CBD) is the only licensed CBMP for epilepsy in the UK; however, specialist clinicians may prescribe high-CBD unlicensed specials for appropriate patients.

Inflammatory Conditions

CBD’s interaction with CB2 receptors — alongside the anti-inflammatory CB2 agonist activity of the terpene caryophyllene — makes high-CBD, caryophyllene-rich strains a logical consideration for inflammatory pain conditions such as rheumatoid arthritis, inflammatory bowel disease, and fibromyalgia. ACDC and Charlotte’s Web are frequently cited in this context.

How UK Doctors Prescribe Cannabis Strains

In the UK, medical cannabis can only be prescribed by a specialist clinician (consultant-level) on the GMC register. General practitioners cannot initiate cannabis prescriptions, though they may be involved in shared care arrangements. The prescribing process typically involves:

1. Initial assessment — A specialist consultation reviewing your diagnosis, medical history, previous treatments trialled, and current medication.
2. Treatment planning — If cannabis is appropriate, the clinician selects a specific product (defined cultivar, cannabinoid ratios, format) and starting dose.
3. Prescription issuance — A Schedule 2 controlled drug prescription is issued, valid for 28 days.
4. Pharmacy dispensing — The prescription is fulfilled by a licensed specialist pharmacy. All products must meet the pharmacist’s quality assurance checks.
5. Review appointments — Regular follow-ups assess treatment response, tolerability, and dose adjustments.

Cannamedical Britannia works directly with prescribing clinics and dispensing pharmacies across the UK to ensure that EU-GMP certified products with verified cannabinoid profiles are available within the formularies that clinicians need. Our clinical team provides product documentation, certificates of analysis, and formulary support to healthcare professionals. For clinicians seeking product information or partnership enquiries, visit our clinician hub or find a participating prescriber near you.

Patients considering medical cannabis should approach their GP or specialist in the first instance. The medical cannabis pathway in the UK has become significantly more accessible since 2018, with thousands of patients now successfully managed on prescribed CBMPs through established clinical networks.

---

Sources: Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology. 2011;163(7):1344-1364. | Project CBD: Terpenes and the Entourage Effect. | Cannamedical EU-GMP Portfolio Documentation (internal). | NICE Technology Appraisal TA459: Cannabidiol for treating Dravet syndrome and Lennox-Gastaut syndrome. | MHRA: Cannabis-based products for medicinal use guidance, updated 2023.

Medically reviewed by the Cannamedical Britannia Clinical Team, May 2026.